Silver Book

Silver Book Fact

Flu vaccine use reduces disease burden

Use of the LAIV (live attenuated influenza virus) in healthy adults ages 18 to 64 reduced febrile illness by 19% and upper respiratory tract illnesses by 24%. It also reduced the days of illness by 23% to 27% depending on severity of illness, lost work days by 18% to 28%, and days with visits to health care professionals by 25% to 41%.

Nichol, Kristin L., April Lind, Karen L. Margolis, Maureen Murdoch, Rodney McFadden, et al. The Effectiveness of Vaccination Against Influenza in Healthy, Working Adults. NEJM. 1995; 333(14): 889-93. http://www.nejm.org/doi/full/10.1056/NEJM199510053331401

Reference

Title
The Effectiveness of Vaccination Against Influenza in Healthy, Working Adults
Publication
NEJM
Publication Date
1995
Authors
Nichol, Kristin L., April Lind, Karen L. Margolis, Maureen Murdoch, Rodney McFadden, et al.
Volume & Issue
Volume 333, Issue 14
Pages
889-93
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Only a 20% reduction in drug-resistant infections would save $3.2 – $5.2 billion each year
    A 20% reduction in drug-resistant infections would save between 5.7 and 11.3 million additional hospital days and between $3.2 and $5.2 billion in healthcare costs, each year.  
  • Negative value of antibiotics to drug companies
    The value of an antibiotic to a drug company is negative $50 million- compared to the positive value of $1 billion for a new musculoskeletal drug.  
  • Flu vaccine use reduces disease burden
    Use of the LAIV (live attenuated influenza virus) in healthy adults ages 18 to 64 reduced febrile illness by 19% and upper respiratory tract illnesses by 24%. It also…  
  • Global use of vaccine prevents death
    Compared to estimated deaths without vaccination, global use of vaccination in 2001 prevented: 61% of measles deaths; 69% of tetanus deaths; 78% of pertussis (whooping cough) deaths; 94% of diphtheria…  
  • Cost-effectiveness of flu vaccine
    Vaccination for pandemic influenza (pH1N1) prior to an outbreak produces incremental cost-effectiveness ratios for individuals without high risk conditions, ranging from $8,000 to $52,000 per quality-adjusted life year.